Hannah Asghari, M.D.

(877) 460-4673
Hannah Asghari, M.D.
Medical Oncologist and Hematologist
Clinical Expertise
  • Medical Oncology
Academic Appointments
  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Medical Oncology & Therapeutics Research

I am dedicated to providing exceptional patient-centered care.

Hannah Asghari, M.D., is a high-achiever noted for academic scholarship and dedication to her patients. A board-certified physician specializing in hematology and oncology, Dr. Asghari feels “deeply privileged to help guide patients during their most trying times.”

Dr. Asghari is a summa cum laude graduate of University of Florida, where she studied biochemistry and molecular biology. She received her medical degree at UF and continued her training at Johns Hopkins Hospital in Baltimore, followed by a hematology/oncology fellowship at University of South Florida based at Moffitt Cancer Center in Tampa, Florida.

Dr. Asghari says she’s known “since childhood” that she wanted to be a physician. She’s delighted to join the City of Hope® family. “City of Hope,” she said, “is on the cutting edge of research and provides outstanding patient care.”

Location

Education & Experience

Board Certifications

  • 2020, American Board of Medical Oncology
  • 2020, American Board of Hematology
  • 2017, American Board of Internal Medicine

Degrees

  • 2014, M.D., Doctor of Medicine, University of Florida, Gainesville, FL
  • 2009, B.S., Bachelor of Science, University of Florida, Gainesville, FL

Fellowship

  • 2017–2020, Fellow, Hematology and Oncology, University of South Florida/Moffitt Cancer Center, Tampa, FL

Residency

  • 2014–2017, Resident, Internal Medicine, Johns Hopkins Hospital, Baltimore, MD

Professional Experience

  • 2020–present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Antelope Valley, CA

Awards & Memberships

Awards

  • 2024-2025, Super Doctors Southern California Rising Stars
  • 2019, American Society of Hematology Abstract Achievement Award
  • 2019, Moffitt Scientific Symposium Featured Poster Presentation Award
  • 2014, Caranasos Medical Student Professionalism Award
  • 2013, Gold Humanism Honor Society
  • 2013, UF College of Medicine Alumni Scholarship for Academic Excellence
  • 2007, Distinguished Anderson Scholar

Memberships

  • 2020, American Society of Clinical Oncology
  • 2020, American Society of Hematology

Publications

  • Asghari H, Talati C. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. Current Opinion in Hematology. 9000; Publish Ahead of Print. DOI: 10.1097/MOH.0000000000000568.
  • Asghari, H. and Lancet, J. E. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Leukemia & Lymphoma. 2020:1-8. DOI:10.1080/10428194.2020.1719093.
  • Asghari H, Mo Q, Naqvi SM, Nishihori T, Hansen D, Ahmad A, Elmariah H, Lazaryan A, Davilla M, Faramand R, Khimani F, Mishra A, Perez L. Nieder M, Pidala J, Anasetti C, Bejanyan N. Composite Disease Risk Comorbidity Index (DRCI) Predicts Survival of Older Adults with AML or MDS Receiving Allogeneic Hematopoietic Cell Transplantation (In Submission).

Abstracts and Poster Presentations

  • Asghari H, Mo Q, Naqvi SM, Lazaryan A, Davila ML, Nishihori T, Khimani F, Mishra A, Perez LE, Elmariah H, Liu H, Nieder M, Fernandez H, Pidala JA, Anasetti C, Bejanyan N. (2019). Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices. 2019 Transplantation & Cellular Therapy Meeting of ASBMT and CIBMTR. Biology of Blood and Marrow Transplantation, 25(3), S124-S125. DOI:10.1016/j.bbmt.2018.12.406
  • Asghari H, Talati C, Achille A, Powers J, Sahakian E, Chan O, Isenalumhe L, Nodzon L, Sweet K, Pinilla-Ibarz J. (2019). Comparison of Digital Droplet Polymerase Chain Reaction (ddPCR) Technology to Real Time Quantitative PCR (RT-qPCR) for Detection of BCR-ABL p210 Transcript upon Tyrosine Kinase Inhibitor Discontinuation in Patients with CP-CML. 21ST Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Bordeaux, France, September 12-15, 2019.
  • Chan O, Jennings M, Asghari H, Song J, Hussaini M, Sallman D, Padron E, Komrokji R, List A, Lancet J, Mishra A, Sweet K, Talati C. (2019). RUNX1 Mutation is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia (AML) who Received Allogeneic Stem Cell Transplantation (allo-SCT). 2019 Society of Hematologic Oncology Annual Meeting. Clinical Lymphoma, Myeloma and Leukemia, 19, S233. DOI:10.1016/j.clml.2019.07.119
  • Asghari H, Lee D, Deutsch YE, Chan O, Al Ali N, Boisclair S, Brahim A, Padron E, Kuykendall A, List A, Fernandez H, Lancet J, Sallman D, Komrokji R, Sweet K, Talati C. HANNAH H. ASGHARI, M.D. PAGE 3 (2019). Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 1357-1357. DOI:10.1182/blood-2019-128958
  • Asghari H, Lee D, Deutsch YE, Chan O, Al Ali N, Boisclair S, Terrell C, Padron E, Kuykendall A, List A, Fernandez H, Lancet J, Sallman D, Komrokji R, Sweet K, Talati C. (2019). Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 3895-3895. DOI:10.1182/blood-2019-130379
  • Asghari H, Talati C, Achille A, Powers JJ, Sahakian E, Chan O, Shelton D, Isenalumhe L, Nodzon L. Sweet K, Pinilla Ibarz J. (2019). Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 3382-3382. DOI: 10.1182/blood-2019-131207
  • Chan O, Hunter A, Talati C, Sallman DA, Asghari H, Song J, Hussaini M, Bejanyan N, Elmariah H, Kuykendall A, Padron E, Komrokji R, List A, Lancet J, Sweet K, Mishra A. (2019). Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 149-149. DOI:10.1182/blood-2019-131530
  • Chan O, Talati C, Asghari H, Bejanyan N, Elmariah H, Hussaini M, Khimani F, Kim J, Komrokji R, Kuykendall A, Lancet J, List A, Nieder M, Nishihori T, Padron E, Perez L, Pidala J, Song J, Zhou J, Sallman D. Sweet K, Mishra A. (2019). Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome. 2019 American Society of Hematology Annual Meeting. Blood, 134(Supplement_1), 4621-4621. DOI:10.1182/blood-2019-130922

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
5.0
Spend enough time with you
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Rate provider 0-10
02/28/26
Great services at City of Hope. - Verified patient
02/05/26
Dr Asghari and her entire staff are awesome - Verified patient
12/30/25
Already have recommended. - Verified patient
12/29/25
Very satisfactory. - Verified patient
12/25/25
This provider is very thorough in her explanations so I follow the information and instructions with ease! - Verified patient